Seven Eight Capital’s Medifast MED Stock Holding History

Seven Eight Capital’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-4,000	Closed	-$250K	–	483
2020 Q1	$250K	Buy	+4,000	New	+$364K	0.06%	354
2019 Q2	–	Sell	-6,072	Closed	-$774K	–	675
2019 Q1	$774K	Buy	+6,072	New	+$770K	0.04%	391
2018 Q4	–	Sell	-9,500	Closed	-$2.1M	–	643
2018 Q3	$2.1M	Buy	+9,500	New	+$1.93M	0.13%	234

Other funds holding MED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Seven Eight Capital's MED Position: Q2 2020 in Review

Seven Eight Capital sold out of Medifast (MED) in Q2 2020, closing a stake of 4,000 shares — an estimated $250K sold.

Seven Eight Capital first reported a position in MED in Q3 2018 and held it in 3 quarters. The position peaked at $2.1M in Q3 2018. 224 funds tracked by Wall St. Rank hold MED as of Q2 2020.

Seven Eight Capital reported no remaining Medifast position as of Q2 2020 after selling out during the quarter.
Seven Eight Capital sold 4,000 Medifast shares in Q2 2020, an estimated $250K.
Seven Eight Capital first reported a position in Medifast in Q3 2018 and held it in 3 quarters.
Seven Eight Capital's Medifast position peaked at $2.1M in Q3 2018.
224 funds tracked by Wall St. Rank held Medifast as of Q2 2020.

Based on Seven Eight Capital's 13F filing for Q2 2020, filed 6 Aug 2020.